Abstract:Objective: Cytokines and cell subsets are important components of the tumor microenvironment. Previous research has revealed that there are differences in cytokines and cell subsets in the peripheral blood of lung cancer (LCA) patients before and after eradication. The purpose of this study is to explore the monitoring value of cytokines and cellular subpopulations as biomarkers in post-immunotherapy monitoring of patients with LCA after surgery Methods: We conducted a case-control study using double-antibody sandwich magnetic microsphere flow cytometry with immunofluorescence technology and fluorescent monoclonal antibody multiparameter flow cytometry to detect differences in peripheral blood cytokines and cell subsets between LCA patients after immunotherapy and healthy controls. Results: Our research results show that there are differences in the levels of IL-4, IL-6, IL-10, IL-17, IFN-γ, TNF-α in the peripheral blood of LCA patients (n=70) after immunotherapy compared to the healthy controls (n=55) ( P<0.05 ), and there are differences in 10 cell subgroups including DP T Cells, AT cells, and NLR in the peripheral blood compared to the healthy controls (n=35) ( P<0.05 ). Further analysis revealed significant differences in the detection data of IL-6, IL-10, IFN-γ, CD56 dim NK cells, Total B cells, Total NE cells, CD15 + M cells, and NLR between LCA deceased patients (n=25) and LCA surviving patients (n=27) during the same period ( P<0.05 ). The continuous monitoring of cytokines and cell subsets is far more valuable than a single-time test, as abnormal fluctuations in the data of cytokines and cell subsets are often associated with poor prognosis. In addition, IL-6 and NLR showed the strongest discriminative ability between postoperative immunotherapy-treated LCA patients and healthy controls, with AUC values of 0.840 and 0.822, respectively. There was a significant association between IFN-γ and distant metastasis in LCA ( P<0.05 ), as well as between CD56 dim NK cells and lymph node infiltration ( P<0.05 ). Conclusion: This research results support peripheral blood cytokines and cell subsets as biomarkers for monitoring the postoperative immune status and predicting the prognosis of LCA patients after immunotherapy. The continuous monitoring of cytokines and cell subsets is far more valuable than a single-time detection.

The Changes of Peripheral Blood Lymphocyte Subsets and Cytokine in Patients with Lung Adenocarcinoma at Different Stages

Detection of T Lymphocyte Subsets in the Peripheral Blood of Patients with Advanced Lung Adenocarcinoma

Identification of Stage-associated MicroRNAs in Lung Adenocarcinoma Based on Microarray Data

[Quantitative Studies on Expression of Peripheral Blood CD44 and CD54 in Non-Small Cell Lung Carcinoma].

Changes Of Tumor Markers And C Reactive Protein In Different Status Of Lung Cancer

Study on Peripheral Blood T Lymphocyte Subsets of Patients with Lung Cancer and Lung Infection

Role of peripheral cytokines in lung cancer pathological typing and prognosis

Differences in Serum Cytokine Levels Distinguish Between Clinically Noninvasive Lung Adenocarcinoma and Invasive Lung Adenocarcinoma: A Cross‐sectional Study

Clinical significance of expression rate of cytokines in peripheral blood cells of patients with lung cancer

Analysis on the Change of Peripheral Blood T Lymphocyte Subsets Before and after Chemotherapy in Patients with Non-Small Cell Lung Cancer

Analysis of NK/T and Treg cell in peripheral blood of patients with different malignancies during the chemotherapy

Changes of immune pattern in lung cancer patients before and after chemotherapy

Observation of Changes in Peripheral Lymphocyte Subsets by Flow Cytometry in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel and Cisplatin

Elevations of monocyte and neutrophils, and higher levels of granulocyte colony-stimulating factor in peripheral blood in lung cancer patients

Immune Function Changes of Non-Small Cell Lung Cancer Patients after Chemotherapy

Alterations of Serum Inflammatory Biomarkers in the Healthy and Lung Cancer Patients Before and Post Chemotherapy

Prognostic significance of peripheral and tumor-infiltrating lymphocytes in newly diagnosed stage III/IV non-small-cell lung cancer

The effects of postoperative targeted immunotherapy on peripheral blood cytokines and immune cell profile in lung cancer patients

Clinical significance of regulatory T cell in peripheral blood in patients with lung cancer

Frequency changes in HLA‐I alleles: A marker to guide immunotherapy in lung adenocarcinoma patients and its relationship with tumor mutational burden and PD‐L1 expression

The Relationship Between Lymphocyte Subsets and the Prognosis and Genomic Features of Lung Cancer: A Retrospective Study